

Cahill Represents Financing Sources in Valeant - Biovail Merger

Date: 09/28/10

Cahill represented the Administrative Agent and Arrangers, in connection with \$2,750,000,000 of senior secured credit facilities to finance the merger of Valeant Pharmaceuticals International and Biovail Corporation and related refinancing of certain existing indebtedness.

Cahill also represented the joint book-running managers in a Rule 144A/Reg S offering of two tranches of Senior Notes by Valeant Pharmaceuticals International, consisting of \$500,000,000 of 6.75% Senior Notes due 2018 and \$700,000,000 of 7.00% Senior Notes due 2020. A portion of the proceeds of the Senior Notes was used to finance the merger.

Attorneys

- Noah B. Newitz
- Timothy B. Howell
- Josiah M. Slotnick